Dynavax Technologies

366 articles with Dynavax Technologies

• 

  Clinical Catch-up from Last Week: June 1-June 7

  6/10/2019

  Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
• 

  Sizable Layoffs Hit Four Life Science Companies

  6/6/2019

  Hundreds lose their jobs as companies close facilities and shift business focuses.
• 

  Dynavax to Lay Off 37% of Staff, CEO to Retire as Company Restructures

  5/24/2019

  Dynavax plans to step away from immuno-oncology development and will lay off 37% of its staff as a result.
• 

  Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails in Phase IIa Trial

  11/30/2018

  Asthma drug failed to show a statistically clinical improvement in controlling asthma, Dynavax said.
• 

  Dynavax Secures $175 Million in Funding to Support Launch of Recently Approved Heplisav-B

  2/20/2018

  Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.

• Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb. 5, 2018

  2/5/2018

  These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).

• Dynavax Technologies Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

  1/15/2018

  Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.85 per share.

• Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults

  1/8/2018

  HEPLISAV-B can now be ordered through a network of distributors, which will broaden over the next few weeks.

• Dynavax Technologies Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  12/6/2017

  Dynavax granted stock options to purchase shares of Dynavax's common stock to the new employees with an exercise price of $18.40 per share.

• 

  How Sweet It Is: Dynavax Finally Wins FDA OK for Hep B Vaccine Heplisav

  11/10/2017

  The FDA approved Dynavax's Heplisav-B, it's first new hepatitis B vaccine in the U.S. in more than 25 years.

• Dynavax Reports Third Quarter 2017 Financial Results

  11/3/2017

  Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016.

• 

  6 Biotechs Facing Make-or-Break FDA PDUFA Catalysts in November

  10/31/2017

  Here's a closer look at six drugs facing FDA decisions in November.

• Dynavax Initiates Clinical Trial In Non-Small Cell Lung Cancer With A Novel Inhaled TLR9 Agonist In Combination With Anti-PD-1 Therapy

  10/19/2017

  Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).

• Bay Area's Dynavax Quietly Shops Around Its Almost-Approved Hep B Vaccine

  10/3/2017

• Dynavax To Present At Upcoming Investor Conferences

  9/5/2017

• Dynavax Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock

  8/16/2017

• Dynavax Announces Proposed Public Offering Of Common Stock

  8/9/2017

• Dynavax Shares Plunge on Delayed FDA Decision for Hep B Vaccine Heplisav

  8/4/2017

• Dynavax Reports Second Quarter 2017 Financial Results

  8/2/2017

• FDA Panel Votes to Recommend Dynavax's Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline's Engerix-B

  7/31/2017